Evaluation objectives

To ensure the successes, challenges and lessons learned from the COVAX Facility and COVAX Advance Market Commitment (AMC) are independently evaluated and documented, both from a learning and an accountability perspective, Gavi commissioned a COVAX Facility and COVAX AMC evaluability assessment and evaluation design study to:

• assess the readiness for an evaluation, including the coherence and completeness of the COVAX Facility and COVAX AMC design, the availability of data to answer the evaluation questions (EQs), and the usefulness of doing so; and
• set out an appropriate and robust multi-stage evaluation design, using the findings of the above, that can be utilized over the life course of the COVAX Facility and COVAX AMC.

Methods

This evaluability assessment and evaluation design study was informed by an extensive literature review, as well as KIIs with Secretariat, Alliance Partners, and global- and country-level stakeholders.

Findings and conclusions

Overall, the assessment concluded the COVAX Facility and COVAX AMC design is coherent and complete enough for a robust evaluation and recommended a 10-year horizon evaluation (2022-2030), in line with the initially envisaged life span for the COVAX Facility and COVAX AMC.

A Formative Review and Baseline Study will be conducted over the period 2022-2023 and constitute ‘Phase 1’ of the multi-stage evaluation.

For further details on the findings of the evaluability assessment and the purpose, principles and strategic direction of the multi-stage evaluation, please see the full report.

Documents

Gavi’s COVAX Facility and COVAX AMC Evaluability Assessment and Evaluation Design Study

• Final report